Synapse Open Synapse
Biology

STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

STAT News · · 1 min read

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.

Latest from STAT News